The Viamet Group discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our promising clinical and preclinical candidates include potential therapies to treat invasive and hospital-based fungal infections, cancer, cardiovascular and orphan diseases. Focusing on the needs of patients and clinicians, and utilizing our proprietary MIDAS (Metalloenzyme Inhibitor Design And Synthesis) technology, we design our drug candidates to achieve superior efficacy and safety profiles compared to currently marketed drugs.
The Viamet Group of companies consists of Viamet Pharmaceutical Holdings, LLC. and its operating subsidiaries VPS-2, Inc., VPS-3, Inc. and Viamet Pharmaceuticals (Bermuda), Ltd. We are supported by a leading group of corporate and institutional investors including A&B Equity Holdings, LLC, Astellas Venture Management, Cormorant Asset Management, LLC, Hatteras Venture Partners, Headlands Ventures, Intersouth Partners, Lilly Ventures, Malin, Novartis Venture Fund, and Woodford Investment Management.
Robert Schotzinger, M.D., Ph.D.
President & Chief Executive Officer and Director
Dr. Schotzinger brings over 20 years of research, development and management experience to the Viamet Group. Prior to joining the Viamet Group, Dr. Schotzinger was President and CEO of BioStratum Inc., a privately-held biotechnology company. Dr. Schotzinger began his pharmaceutical career at Abbott Laboratories where he held positions of increasing responsibility, including Director of International Medical Affairs and Vice President of Drug Development. While at Abbott, he gained experience in preclinical and clinical drug development and was involved in the filing and approval of multiple NDAs, SNDAs, ANDAs and INDs.
Dr. Schotzinger received his B.S. in pharmacy from the Ohio State University. He subsequently earned his Ph.D. in pharmacology and M.D. from Case Western Reserve University. He also completed a residency at the University of Virginia, which led to Board Certification in Internal Medicine.
General Partner, Hatteras Venture Partners and Chairman
Former Executive Vice President, Finance and Business Development and Chief Financial Officer, Allergan, Inc.
Andrew von Eschenbach, M.D.
Former Commissioner, U.S. Food and Drug Administration
Adrian Howd, Ph.D.
Chief Executive Officer, Malin Corporation plc.
Executive Vice President, Malin Corporation plc.
Douglas Reed, M.D.
General Partner, Hatteras Venture Partners
Robert Schotzinger, M.D., Ph.D.
President & Chief Executive Officer
S. Edward Torres
Managing Director, Lilly Ventures
Venture Partner, Intersouth Partners
Managing Director, Novartis Venture Fund
Chief Investment Officer, Lurie Holdings
We have developed a chemistry and biology technology platform that enables the discovery of highly differentiated metalloenzyme inhibitors across a broad range of therapeutic applications. We refer to our proprietary platform as the MIDAS technology (Metalloenzyme Inhibitor Design And Synthesis). Our core expertise comprises a deep understanding of over 150 potential metalloenzyme targets, proprietary computer-based design tools and a library of unique metal-binding groups (MBG).
Metalloenzymes are distinguished from other enzymes in that they contain a metal, such as iron or zinc, at the core of the enzyme active site. The metal has frequently been a target for pharmaceutical intervention, and approximately 10% of all marketed drugs act by inhibiting metalloenzymes.
We improve upon existing therapies through a two-step process. Using the MIDAS technology we design inhibitors that contain novel MBG that deliver a high degree of selectivity for the desired metalloenzyme target, while maintaining high target potency. Ultimately, our goal is to deliver candidates with clinically relevant improvements in therapeutic index; which may provide for both superior safety and efficacy profiles compared to existing therapies.
We are utilizing our MIDAS technology to design novel drugs that we expect to have improved potency, greater selectivity and superior therapeutic index. Our initial drug discovery and development efforts have been focused on a clinically validated metalloenzyme target, fungal CYP51, with broad applications in the treatment of human fungal infections. This approach includes VT-1598, an orally available inhibitor of fungal CYP51 that has shown high potency and selectivity in in vitro studies. An IND has been approved for VT-1598 and the molecule is ready to enter clinical testing for a range of invasive fungal infections, including cryptococcal meningitis. Our pipeline also includes promising preclinical product candidates which target other validated metalloenzymes in the areas of cardiovascular disease and oncology. We believe that our MIDAS technology is applicable to a broad range of metalloenzyme targets across many therapeutic indications.
Our drug development success using the MIDAS technology was recently validated through the acquisition of our Viamet Pharmaceuticals subsidiary and the VT-1161 program by NovaQuest Capital Management, LLC. VT-1161 had successfully completed Phase 2b clinical trials in onychomycosis (toenail fungus) and recurrent vulvovaginal candidiasis (RVVC).